STUDY BASICS
Are you the parent of a child ages 4-7? Are they allergic to peanuts? You and your child may be eligible for a research study to evaluate an investigational drug patch called DBV712 for 4-7 year old children with peanut allergy. Compensation is provided.
STUDY PURPOSE
This study is evaluating an investigational drug patch called DBV712 for 4 to 7 year old children with peanut allergy. The main purpose of this study is to learn how well the study drug patch (DBV712) works and how safe it is compared with a placebo patch in children with peanut allergy. The small amount of peanut protein in the study drug patch is designed to potentially desensitize (or make less sensitive) a peanut-allergic person by repeated exposures to very small amounts of peanut via the skin. You and your child will be asked to attend at least 12 study visits over a period of approximately 58 weeks (about 1 year) during which you will apply one study drug patch per day to your child's back.
COULD THIS STUDY BE RIGHT FOR YOUR CHILD?
Eligible participants are children:
- Ages 4-7
- Currently following a strict peanut-free diet
- Diagnosed with peanut allergy
WHAT PARTICIPANTS CAN EXPECT
This study is divided into 3 periods: a screening period, a study treatment period, and a follow-up period. During each study period, you and your child will have 1 or more visits with the study doctor at the center. The screening visits will last about 3-4 hours, the double-blind placebo-controlled food challenge visits may last up to 6 hours, and all other visits will last about 2-3 hours.
If your child qualifies for study participation, they will:
- Be randomly assigned (by chance) to receive the study drug (DBV712) patch or placebo patch. Participants will have about a 67% (2 in 3) chance of receiving the DBV712 patch and about a 33% (1 in 3) chance of receiving the placebo patch.
- Attend 12 study visits to a research clinic
- Receive 5 calls from research staff
- Maintain a daily eDiary to record treatment details, including time of application/removal of the patch each day and other patch related details
- Apply daily patch to their back
- Have an emergency action plan in case of allergic reactions
- Have physical exams, medical exams, and blood tests
- Undergo a second 2 day food challenge to determine how well the treatment has worked after 12 months of treatment
IRB: PRO00069099
- A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy with DBV712 250 μg in 4-7-year-old Children with Peanut Allergy (VITESSE)MEET THE RESEARCHER
Deborah Albright
Deborah Albright, MD, is an allergy & immunology specialist in Pittsburgh. A graduate of the University of Pittsburgh, Dr. Albright’s research interests include allergy & immunology and pediatrics.